Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Very Bullish +85

StockWatch: Agilent Shares Jump on Better than Expected Quarterly Results

📈 Agilent Technologies shares surged 17% on Thursday, marking their best one-day increase in nearly 24 years following better-than-expected quarterly results.

💰 The company reported Q2 FY2026 net income of $339 million, a 58% year-over-year increase driven by revenue growth of 10% to $1.835 billion.

📊 Core organic growth reached 6.3%, surpassing analyst consensus forecasts and the company's own previous guidance range of 4% to 5.5%.

🚀 Management raised its full-year 2026 revenue guidance, adjusting the range from $7.3 billion to $7.49 billion after beating expectations.

💹 Operating margin guidance was increased by 10 basis points to a range of 75% to 85%, while non-GAAP EPS guidance rose eight cents at the midpoint.

🤖 CEO Padraig McDonnell highlighted that pharma customers are leveraging AI to accelerate drug development, which is expected to increase demand for wet lab investments and downstream manufacturing tools.

📈 J.P. Morgan analyst Casey Woodring reiterated an "Overweight" rating with a $180 price target, citing long-term upside from reshoring and CDMO capacity ramping.

🔬 Leerink Partners maintained an "Outperform" rating and raised its 12-month price target to $170 based on the improved guidance and strong market position.

🔄 BofA Securities upgraded Agilent from "Neutral" to "Buy," though they lowered their price target slightly to $145 while maintaining a lower earnings multiple estimate.

📉 The stock closed the week at $135.54, delivering an 18% gain for the week and achieving seven consecutive days of positive trading activity.

🧬 Growth was particularly strong in core pharma and biotech tools segments, which exceeded Wall Street expectations cited by FactSet data.

🌍 The company operates on a fiscal year ending October 31, with this report covering the second quarter of its 2026 fiscal year ending April 30.

📉 Currency fluctuations and acquisitions were excluded from the core growth calculation to provide a clearer view of organic performance.

🔬 Agilent's leading position in downstream manufacturing QA/QC workflows is expected to benefit from a higher number of drug approvals coming through the pipeline.

🧪 Analysts note that AI-driven shortening of target identification timelines could increase wet lab validation volume, benefiting high-throughput instrument providers like Agilent.

Bullish Signals
  • Agilent shares surged 17% on Thursday, marking their best one-day increase in nearly 24 years following better-than-expected quarterly results.
  • The company reported net income of $339 million or $1.20 per share, representing a 58% year-over-year increase compared to $215 million last year.
  • Revenue rose 10% to $1.835 billion, exceeding the consensus forecast of $1.79 billion and beating analyst expectations.
  • Agilent raised its full-year 2026 revenue guidance from a low end of $7.3 billion to $7.39 billion, signaling strong confidence in future growth.
  • Operating margin guidance was increased by 10 basis points to 85%, and non-GAAP EPS guidance was raised by eight cents at the midpoint to range between $6.00 and $6.10.
  • Core growth excluding currency and M&A activity reached 6.3%, surpassing the analyst consensus forecast of 4.8% and the company's previous guidance.
  • Shares closed the week with an 18% gain after seven consecutive positive trading days, demonstrating sustained investor enthusiasm.
  • Analysts from J.P. Morgan maintain an 'Overweight' rating with a price target of $180, citing upside potential from reshoring and AI investments in pharma.
  • Leerink Partners raised its 12-month price target to $170 and maintained an 'Outperform' rating based on the improved guidance.
  • BofA Securities upgraded its rating from 'Neutral' to 'Buy', highlighting key growth drivers like LC and GC replacement cycles that remain in early innings.
Risk Factors
  • Agilent raised the low end of its FY 2026 revenue guidance from $7.3 billion to $7.39 billion while simultaneously trimming the upper end from $7.5 billion to $7.49 billion, indicating a narrowing of expected growth range.
  • Analyst consensus predicts an EPS of $5.97 for FY 2026, which is lower than Agilent's revised guidance range of $6.00 to $6.10, suggesting potential over-optimism in management's projections.
  • BofA Securities analyst Michael Ryskin downgraded his price target from $150 to $145 and reduced his earnings multiple estimate from 19x EBITDA to 18x EBITDA for FY 2027, reflecting a more cautious valuation stance.
  • J.P. Morgan analysts warn that AI-driven shortening of timelines could pressure lower-throughput and animal-model-adjacent tools, potentially creating headwinds in specific product segments despite overall growth.
  • Agilent's strong performance is partly attributed to weather-related headwinds seen in the first quarter of FY2026, which may have artificially inflated Q2 results compared to a normalized baseline.
Full Analysis
Agilent Technologies (NYSE: A) shares surged approximately 17% on Thursday, reaching $135.42, marking the stock's best one-day performance in nearly 24 years following a strong second-quarter fiscal 2026 earnings report that exceeded analyst expectations. The company reported net income of $339 million, or $1.20 per share, representing a 58% year-over-year increase compared to $215 million in the same quarter last year. Revenue grew by 10% to $1.835 billion, driven primarily by growth in its core pharma and biotech tools segments, which helped push core organic growth to 6.3%, surpassing both Wall Street consensus forecasts of 4.8% and the company's own prior guidance range of 4% to 5.5%. In response to the positive results, Agilent raised its full-year fiscal 2026 revenue guidance from a low end of $7.3 billion to $7.39 billion and an upper end of $7.5 billion to $7.49 billion. The company also increased its operating margin outlook by 10 basis points to 85% and raised its non-GAAP EPS guidance for the year to a range of $6.00 to $6.10, up from the previous midpoint of $5.97. CEO Padraig McDonnell highlighted that customers are increasingly leveraging artificial intelligence to accelerate drug development, which is expected to increase demand for wet lab validation and downstream manufacturing quality assurance workflows where Agilent holds a leading position. Following the earnings release, several major investment banks upgraded their outlook on the stock. J.P. Morgan maintained an "Overweight" rating with a $180 price target, citing long-term upside from reshoring trends and AI investments in pharma. Leerink Partners kept its "Outperform" rating but raised its 12-month price target to $170 based on the improved guidance. BofA Securities upgraded its rating from "Neutral" to "Buy," though it adjusted its price target slightly to $145, maintaining a positive view on key growth drivers like liquid and gas chromatography replacement cycles.